ホーム/MRK

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze MRK in workspace
MRKNYSE/health care

Merck & Co., Inc.

$124.03Up+0,49 (+0,40%)
Research reviewed: 2026年7月12日 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Merck & Co., Inc. operates in Pharmaceuticals within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
123,58
Hoch
124,74
Tief
122,44
Marktkapitalisierung
306,33 Mrd.
KGV
34.94
52-Wochen-Hoch
--
Dividende
2.750%
Quartalsdividende
--

3-month price context

直近3か月の推移を表示し、フル調査ワークスペースに進む前に短期構造を把握できます。

Investment thesis

Base case
Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. The base case remains conditional on keytruda concentration staying manageable.
Bull case
Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.
Bear case
Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.
Thesis invalidation
Reassess the thesis if merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks.

Key catalysts

  • Oncology franchise growth

    Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses.

  • New product contributions

    Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products.

  • Late-stage pipeline readouts

    A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Principal risks

  • Keytruda concentration

    Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks.

  • Vaccine demand pressure

    Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches.

  • Business-development charges

    Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.

Latest earnings research

2026 Q1

For the quarter ended March 31, 2026, Merck reported sales growth supported by oncology, animal health, and newer launches; acquisition charges produced a quarterly loss, while management increased its full-year sales and non-GAAP EPS outlook ranges.

Valuation interpretation

  • A durable valuation case requires newer products and late-stage assets to reduce dependence on Keytruda before its loss of exclusivity.
  • Pipeline breadth supports strategic optionality, but acquisition spending and uncertain clinical conversion justify a disciplined execution discount.

Peer research

JNJLLYNVO

Recent news

24/7 Wall St. · vor 8 Stunden

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Trefis · vor 8 Stunden

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Zacks · vor 11 Stunden

FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer

Trefis · vor 13 Stunden

How Does LLY Stock Reach $2,100?

Simply Wall St. · vor 13 Stunden

Merck (MRK) Stock Looks Like A Bargain At This Price

Stocktwits · vor 23 Stunden

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears

Data and research sources

Research updated: 2026年7月12日 00:00 UTC
3 verified sources
Merck Announces First-Quarter 2026 Financial ResultsMerck & Co., Inc. · earningsVerified

Fetched: 2026/7/12 0:00:00 UTC

Published: 2026/4/30 0:00:00

Open original source
Merck Investor RelationsMerck & Co., Inc. · companyVerified

Fetched: 2026/7/12 0:00:00 UTC

Open original source
Merck Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 2026/7/12 0:00:00 UTC

Open original source

Continue in the research workspace

Keep MRK in context, run a multi-agent analysis, and monitor thesis changes.

Analyze MRK free

リサーチシステム全体を見る

各段階には固有の役割があり、次の段階で検証可能な成果を残します。

リサーチ手法市場レポートを読む銘柄を探す

Continue researching this stock

市場アナリスト

市場アナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ファンダメンタルズアナリスト

ファンダメンタルズアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ニュースアナリスト

ニュースアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

リスクマネージャー

リスクマネージャー は リスクと監視 の中で 監視 段階を専門に担い、後続判断の前提を整える役割です。